NCT00744263

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 84,496 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Conditions

• Pneumonia, Pneumococcal
• Pneumococcal Infections
• 13-valent Pneumococcal Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	VACCINE: placebo	0.5 mL, single intra-muscular injection
BIOLOGICAL	VACCINE: 13-valent pneumococcal conjugate vaccine	0.5 mL, single intra-muscular injection

Timeline

• Start date: 2008-09-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2008-08-29
• Last updated: 2014-10-06
• Results posted: 2014-10-06

Locations

159 sites across 1 country: Netherlands